Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice

References

• Bondi MW, Edmonds EC, Salmon DP. Alzheimer’s disease: past, present, and future. J Int Neuropsychol Soc. 2017;23:818–17. doi:10.1017/S135561771700100X.
   PubMed Web of Science ®Google Scholar
• Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179:312–39. doi:10.1016/j.cell.2019.09.001.
   PubMed Web of Science ®Google Scholar
• Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr1–sr1. doi:10.1126/scitranslmed.3002369.
   PubMed Web of Science ®Google Scholar
• Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm. 2010;117:949–60. doi:10.1007/s00702-010-0433-4.
   PubMed Web of Science ®Google Scholar
• Sarlus H, Heneka MT. Microglia in Alzheimer’s disease. J Clin Invest. 2017;127:3240–49. doi:10.1172/JCI90606.
   PubMed Web of Science ®Google Scholar
• van Dyck CH. Anti-amyloid-β monoclonal antibodies for Alzheimer’s disease: pitfalls and promise. Biol Psychiatry. 2018;83:311–19. doi:10.1016/j.biopsych.2017.08.010.
   PubMed Web of Science ®Google Scholar
• Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimer’s Dis. 2012;28:49–69. doi:10.3233/JAD-2011-110977.
   PubMed Web of Science ®Google Scholar
• Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537:50–56. doi:10.1038/nature19323.
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, Burke R-L, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916–19. doi:10.1038/78682.
   PubMed Web of Science ®Google Scholar
• Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368:117–27. doi:10.1056/NEJMoa1211851.
   PubMed Web of Science ®Google Scholar
• Ulland TK, Colonna M. TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol. 2018;14:667–75. doi:10.1038/s41582-018-0072-1.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, Sun Y, Zhu B, Piña-Crespo JC, Zhang M, et al. TREM2 is a receptor for β-amyloid that mediates microglial function. Neuron. 2018;97:1023–31.e7. doi:10.1016/j.neuron.2018.01.031.
   PubMed Web of Science ®Google Scholar
• Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160:1061–71. doi:10.1016/j.cell.2015.01.049.
   PubMed Web of Science ®Google Scholar
• Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O’Loughlin E, Xu Y, Fanek Z, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566–81.e9. doi:10.1016/j.immuni.2017.08.008.
   PubMed Web of Science ®Google Scholar
• Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J Exp Med. 2015;212:287–95. doi:10.1084/jem.20142322.
   PubMed Web of Science ®Google Scholar
• Deczkowska A, Weiner A, Amit I. The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell. 2020;181:1207–17. doi:10.1016/j.cell.2020.05.003.
   PubMed Web of Science ®Google Scholar
• Lee CYD, Daggett A, Gu X, Jiang LL, Langfelder P, Li X, Wang N, Zhao Y, Park CS, Cooper Y, et al. Elevated TREM2 gene dosage reprograms microglia responsivity and ameliorates pathological phenotypes in Alzheimer’s disease models. Neuron. 2018;97:1032–48.e5. doi:10.1016/j.neuron.2018.02.002.
   PubMed Web of Science ®Google Scholar
• Schlepckow K, Monroe KM, Kleinberger G, Cantuti-Castelvetri L, Parhizkar S, Xia D, Willem M, Werner G, Pettkus N, Brunner B, et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol Med. 2020;12:e11227. doi:10.15252/emmm.201911227.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Danao J, Talreja S, Wen P, Yin J, Sun N, Li CM, Chui D, Tran D, Koirala S, et al. TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer’s disease variant Trem2(R47H) on murine myeloid cell function. J Biol Chem. 2018;293:12620–33. doi:10.1074/jbc.RA118.001848.
   PubMed Web of Science ®Google Scholar
• Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, Ward M, Siddiqui O, Paul R, Gilfillan S, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. J Exp Med. 2020;217. doi:10.1084/jem.20200785
   Web of Science ®Google Scholar
• Fassler M, Rappaport MS, Cuño CB, George J. Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer’s disease models. J Neuroinflammation. 2021;18:19. doi:10.1186/s12974-020-01980-5.
   PubMed Web of Science ®Google Scholar
• Price BR, Sudduth TL, Weekman EM, Johnson S, Hawthorne D, Woolums A, Wilcock DM. Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition. J Neuroinflammation. 2020;17:238. doi:10.1186/s12974-020-01915-0.
   PubMed Web of Science ®Google Scholar
• Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2018;9:63–73. doi:10.1007/s13238-017-0473-8.
   PubMed Web of Science ®Google Scholar
• Song W, Hooli B, Mullin K, Jin SC, Cella M, Ulland TK, Wang Y, Tanzi RE, Colonna M. Alzheimer’s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimer’s Dementia. 2017;13:381–87. doi:10.1016/j.jalz.2016.07.004.
   PubMed Web of Science ®Google Scholar
• Ohtsuka M, Arase H, Takeuchi A, Yamasaki S, Shiina R, Suenaga T, Sakurai D, Yokosuka T, Arase N, Iwashima M, et al. NFAM1, an immunoreceptor tyrosine-based activation motif-bearing molecule that regulates B cell development and signaling. Proc Natl Acad Sci U S A. 2004;101:8126–31. doi:10.1073/pnas.0401119101.
   PubMed Web of Science ®Google Scholar
• Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron. 2016;91:328–40. doi:10.1016/j.neuron.2016.06.015.
   PubMed Web of Science ®Google Scholar
• Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, Yeromin AV, Scarfone VM, Marsh SE, Fimbres C, et al. iPSC-Derived human microglia-like cells to study neurological diseases. Neuron. 2017;94:278–93.e9. doi:10.1016/j.neuron.2017.03.042.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhu B, Liu Y, Zhang X, Yin J, Li X, Jiang L, Hodges AP, Rosenthal SB, Zhou L, et al. Multi-omic comparison of Alzheimer’s variants in human ESC-derived microglia reveals convergence at APOE. J Exp Med. 2020;217. doi:10.1084/jem.20200474
   Web of Science ®Google Scholar
• Pardridge WM. Drug transport across the blood–brain barrier. J Cerebral Blood Flow Metab. 2012;32:1959–72. doi:10.1038/jcbfm.2012.126.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yeh SH, Madireddi S, Matochko WL, Gu C, Pacheco Sanchez P, Ultsch M, De Leon Boenig G, Harris SF, Leonard B, et al. Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members. mAbs. 2019;11:996–1011. doi:10.1080/19420862.2019.1625662.
   PubMed Web of Science ®Google Scholar
• Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M, Zhang J, Hoffmann E, Dormeyer W, Stracke J, et al. Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother. 2011;55:2369–78. doi:10.1128/AAC.00215-10.
   PubMed Web of Science ®Google Scholar
• Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, et al. RG7386, a novel tetravalent FAP-DR5 antibody, effectively triggers FAP-dependent, avidity-driven dr5 hyperclustering and tumor cell apoptosis. Mol Cancer Ther. 2016;15:946–57. doi:10.1158/1535-7163.MCT-15-0647.
   PubMed Web of Science ®Google Scholar
• Peng Q, Malhotra S, Torchia James A, Kerr William G, Coggeshall KM, Humphrey Mary B. TREM2- and DAP12-Dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci Signal. 2010;3:ra38–ra. doi:10.1126/scisignal.2000500.
   PubMed Web of Science ®Google Scholar
• Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, Wang D, Gao Y, Zhu Y, Sheng X, et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model. Nat Commun. 2019;10:1365. doi:10.1038/s41467-019-09118-9.
   PubMed Web of Science ®Google Scholar
• Ulrich JD, Ulland TK, Colonna M, Holtzman DM. Elucidating the role of TREM2 in Alzheimer’s Disease. Neuron. 2017;94:237–48. doi:10.1016/j.neuron.2017.02.042.
   PubMed Web of Science ®Google Scholar
• Blank U, Launay P, Benhamou M, Monteiro RC. Inhibitory ITAMs as novel regulators of immunity. Immunol Rev. 2009;232:59–71. doi:10.1111/j.1600-065X.2009.00832.x.
   PubMed Web of Science ®Google Scholar
• Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Schlepckow K, Araque Caballero MÁ, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E, et al. Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Mol Neurodegener. 2019;14:1. doi:10.1186/s13024-018-0301-5.
   PubMed Web of Science ®Google Scholar
• Vilalta A, Zhou Y, Sevalle J, Griffin JK, Satoh K, Allendorf DH, De S, Puigdellívol M, Bruzas A, Burguillos MA, et al. Wild-type sTREM2 blocks Aβ aggregation and neurotoxicity, but the Alzheimer’s R47H mutant increases Aβ aggregation. J Biol Chemistry. 2021;296. doi:10.1016/j.jbc.2021.100631
   PubMed Web of Science ®Google Scholar
• Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016;15:275–92. doi:10.1038/nrd.2015.21.
   PubMed Web of Science ®Google Scholar
• Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Tong R, Kim DJ, Srivastava A, Bedard C, Henne KR, et al. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12(545):eaay1359.
   PubMed Web of Science ®Google Scholar
• Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ, et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med. 2014;6:261ra154. doi:10.1126/scitranslmed.3009835.
   PubMed Web of Science ®Google Scholar
• Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3:84ra44. doi:10.1126/scitranslmed.3002230.
   PubMed Web of Science ®Google Scholar
• Zhao P, Anami Y, Gao P, Fan X, Li L, Tsuchikama K, Zhang N, An Z. Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model. mAbs. 2022;14:2057269. doi:10.1080/19420862.2022.2057269.
   PubMed Web of Science ®Google Scholar
• Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P, Stracke JO, Lau W, Tissot AC, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81:49–60. doi:10.1016/j.neuron.2013.10.061.
   PubMed Web of Science ®Google Scholar
• Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16:677–81. doi:10.1038/nbt0798-677.
   PubMed Web of Science ®Google Scholar
• Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umaña P, Mössner E. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Design Selection. 2016;29:457–66. doi:10.1093/protein/gzw040.
   PubMed Web of Science ®Google Scholar
• Forner S, Kawauchi S, Balderrama-Gutierrez G, Kramár EA, Matheos DP, Phan J, Javonillo DI, Tran KM, Hingco E, da Cunha C, et al. Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer’s disease. Scientific Data. 2021;8:270. doi:10.1038/s41597-021-01054-y.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Comerota MM, Wan D, Chen F, Propson NE, Hwang SH, Hammock BD, Zheng H. An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer’s disease. Sci Transl Med. 2020;12(573):eabb1206.
   PubMed Web of Science ®Google Scholar
• Svoboda DS, Barrasa MI, Shu J, Rietjens R, Zhang S, Mitalipova M, Berube P, Fu D, Shultz LD, Bell GW, et al. Human iPSC-derived microglia assume a primary microglia-like state after transplantation into the neonatal mouse brain. Proc Natl Acad Sci U S A. 2019;116:25293–303. doi:10.1073/pnas.1913541116.
   PubMed Web of Science ®Google Scholar
• Pandya H, Shen MJ, Ichikawa DM, Sedlock AB, Choi Y, Johnson KR, Kim G, Brown MA, Elkahloun AG, Maric D, et al. Differentiation of human and murine induced pluripotent stem cells to microglia-like cells. Nat Neurosci. 2017;20:753–59. doi:10.1038/nn.4534.
   PubMed Web of Science ®Google Scholar
• Barar J, Rafi MA, Pourseif MM, Omidi Y. Blood-brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts. 2016;6(4):225–48. doi:10.15171/bi.2016.30. Epub 2016 Dec 5. PMID: 28265539; PMCID: PMC5326671.
   PubMed Web of Science ®Google Scholar
• Dardiotis E, Siokas V, Pantazi E, Dardioti M, Rikos D, Xiromerisiou G, Markou A, Papadimitriou D, Speletas M, Hadjigeorgiou GM. A novel mutation in TREM2 gene causing Nasu-Hakola disease and review of the literature. Neurobiol Aging. 2017;53:194.e13–.e22. doi:10.1016/j.neurobiolaging.2017.01.015.
   PubMed Web of Science ®Google Scholar
• Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562:605–09. doi:10.1038/s41586-018-0615-z.
   PubMed Web of Science ®Google Scholar
• Stewart R, Hammond SA, Oberst M, Wilkinson RW. The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. J ImmunoTherapy of Cancer. 2014;2:29. doi:10.1186/s40425-014-0029-x.
   Google Scholar
• Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. Ann Translational Med. 2019;7:105. doi:10.21037/atm.2019.01.42.
   PubMed Web of Science ®Google Scholar
• Paloneva J, Mandelin J, Kiialainen A, Bohling T, Prudlo J, Hakola P, Haltia M, Konttinen YT, Peltonen L. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med. 2003;198:669–75. doi:10.1084/jem.20030027.
   PubMed Web of Science ®Google Scholar
• Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14:94–108. doi:10.1038/nri3582.
   PubMed Web of Science ®Google Scholar
• Maeda A, Kurosaki M, Ono M, Takai T, Kurosaki T. Requirement of SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 for paired immunoglobulin-like receptor B (PIR-B)-mediated inhibitory signal. J Exp Med. 1998;187:1355–60. doi:10.1084/jem.187.8.1355.
   PubMed Web of Science ®Google Scholar
• Kiskis J, Fink H, Nyberg L, Thyr J, Li J-Y, Enejder A. Plaque-associated lipids in Alzheimer’s diseased brain tissue visualized by nonlinear microscopy. Sci Rep. 2015;5:13489. doi:10.1038/srep13489.
   PubMed Web of Science ®Google Scholar
• Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci. 2019;22:191–204. doi:10.1038/s41593-018-0296-9.
   PubMed Web of Science ®Google Scholar
• Liao CR, Rak M, Lund J, Unger M, Platt E, Albensi BC, Hirschmugl CJ, Gough KM. Synchrotron FTIR reveals lipid around and within amyloid plaques in transgenic mice and Alzheimer’s disease brain. Analyst. 2013;138:3991–97. doi:10.1039/c3an00295k.
   PubMed Web of Science ®Google Scholar
• Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541:163–66. doi:10.1016/0006-8993(91)91092-F.
   PubMed Web of Science ®Google Scholar
• Xiong F, Ge W, Ma C. Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer’s disease. Alzheimer’s Dementia. 2019;15:429–40. doi:10.1016/j.jalz.2018.10.006.
   PubMed Web of Science ®Google Scholar
• Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, Van Gelder P, Hartmann D, D’Hooge R, De Strooper B, et al. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 2008;27:224–33. doi:10.1038/sj.emboj.7601953.
   PubMed Web of Science ®Google Scholar
• Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med. 2011;3:89ra57. doi:10.1126/scitranslmed.3002156.
   PubMed Web of Science ®Google Scholar
• Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106–18. doi:10.1038/nrneurol.2012.263.
   PubMed Web of Science ®Google Scholar
• Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, Bu G. ApoE4 accelerates early seeding of amyloid pathology. Neuron. 2017;96:1024–32.e3. doi:10.1016/j.neuron.2017.11.013.
   PubMed Web of Science ®Google Scholar
• Spangenberg E, Severson PL, Hohsfield LA, Crapser J, Zhang J, Burton EA, Zhang Y, Spevak W, Lin J, Phan NY, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model. Nat Commun. 2019;10:3758. doi:10.1038/s41467-019-11674-z.
   PubMed Web of Science ®Google Scholar
• Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell. 2016;29:117–29. doi:10.1016/j.ccell.2015.12.008.
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Peng L, Bee JS, Li J, Perry SR, Comer F, Xu L, Cook K, Senthil K, Clarke L, et al. Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody. J Biol Chem. 2018;293:8439–48. doi:10.1074/jbc.M117.818013.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Zhang Y, Zhang Y, C-f X, Wang Y, Pardridge WM. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng. 2008;99:475–84. doi:10.1002/bit.21602.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Pardridge WM. Brain and organ uptake in the rhesus monkey in vivo of recombinant iduronidase compared to an insulin receptor antibody-iduronidase fusion protein. Mol Pharm. 2017;14:1271–77. doi:10.1021/acs.molpharmaceut.6b01166.
   PubMedGoogle Scholar
• Giugliani R, Giugliani L, de Oliveira Poswar F, Donis KC, Corte AD, Schmidt M, Boado RJ, Nestrasil I, Nguyen C, Chen S, et al. Neurocognitive and somatic stabilization in pediatric patients with severe mucopolysaccharidosis type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial. Orphanet J Rare Dis. 2018;13:110. doi:10.1186/s13023-018-0849-8.
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Boado RJ, Giugliani R, Schmidt M. Plasma pharmacokinetics of valanafusp alpha, a human insulin receptor antibody-iduronidase fusion protein, in patients with mucopolysaccharidosis type I. BioDrugs. 2018;32:169–76. doi:10.1007/s40259-018-0264-7.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Lu JZ, Hui EK, Pardridge WM. IgG-single chain Fv fusion protein therapeutic for Alzheimer’s disease: expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol Bioeng. 2010;105:627–35. doi:10.1002/bit.22576.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Zhang Y, Zhang Y, Xia C-F, Pardridge WM. Fusion antibody for Alzheimer’s disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem. 2007;18:447–55. doi:10.1021/bc060349x.
   PubMed Web of Science ®Google Scholar
• Logan T, Simon MJ, Rana A, Cherf GM, Srivastava A, Davis SS, Low RLY, Chiu C-L, Fang M, Huang F, et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell. 2021;184:4651–68.e25. doi:10.1016/j.cell.2021.08.002.
   PubMed Web of Science ®Google Scholar
• Marsh SE, Abud EM, Lakatos A, Karimzadeh A, Yeung ST, Davtyan H, Fote GM, Lau L, Weinger JG, Lane TE, et al. The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function. Proc National Academy Sci. 2016;113:E1316–E25. doi:10.1073/pnas.1525466113.
   PubMed Web of Science ®Google Scholar
• Cherry JD, Olschowka JA, O’Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11:98. doi:10.1186/1742-2094-11-98.
   PubMed Web of Science ®Google Scholar
• Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? Nat Neurosci. 2016;19:987–91. doi:10.1038/nn.4338.
   PubMed Web of Science ®Google Scholar
• Zhao S, Zhu Y, Schultz RD, Li N, He Z, Zhang Z, Caron A, Zhu Q, Sun K, Xiong W, et al. Partial leptin reduction as an insulin sensitization and weight loss strategy. Cell Metab. 2019;30:706–19.e6. doi:10.1016/j.cmet.2019.08.005.
   PubMed Web of Science ®Google Scholar
• Shihan MH, Novo SG, Le Marchand SJ, Wang Y, Duncan MK. A simple method for quantitating confocal fluorescent images. Biochemistry Biophysics Rep. 2021;25:100916. doi:10.1016/j.bbrep.2021.100916.
   PubMedGoogle Scholar
• Zhong L, Wang Z, Wang D, Wang Z, Martens YA, Wu L, Xu Y, Wang K, Li J, Huang R, et al. Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2). Mol Neurodegener. 2018;13:15. doi:10.1186/s13024-018-0247-7.
   PubMed Web of Science ®Google Scholar
• Chen H-M, van der Touw W, Wang YS, Kang K, Mai S, Zhang J, Alsina-Beauchamp D, Duty JA, Mungamuri SK, Zhang B, et al. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Invest. 2018;128:5647–62. doi:10.1172/JCI97570.
   PubMed Web of Science ®Google Scholar
• Hubin E, Verghese PB, van Nuland N, Broersen K. Apolipoprotein E associated with reconstituted high-density lipoprotein-like particles is protected from aggregation. FEBS Lett. 2019;593:1144–53. doi:10.1002/1873-3468.13428.
   PubMed Web of Science ®Google Scholar
• Moore CS, Ase AR, Kinsara A, Rao VT, Michell-Robinson M, Leong SY, Butovsky O, Ludwin SK, Séguéla P, Bar-Or A, et al. P2Y12 expression and function in alternatively activated human microglia. Neurology Neuroimmunol Neuroinflammation. 2015;2:e80. doi:10.1212/NXI.0000000000000080.
   PubMedGoogle Scholar